When considering factors like disease biology and patient needs in drug discovery and development, the goal is to deliver effective and scalable treatments globally by balancing established approaches ...

Present Status and Future Prospects for Adjuvant Therapy of Melanoma: Time to Build upon the Foundation of High-dose Interferon Alfa-2b The high cure rates for patients with Hodgkin's Disease (HD) in ...

According to a 2020 European Commission study, 1 in 17 people affected by a rare disease during their lifetime and a path to a diagnosis that lasts on average five years. This new partnership will ...